SAN FRANCISCO — Sacituzumab govitecan induced response among one-third of platinum-ineligible patients with metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy, according to study results.
The agent also exhibited a manageable safety profile, researchers reported at ASCO Genitourinary Cancers Symposium.
The data indicate further evaluation of sacituzumab govitecan for metastatic urothelial carcinoma after checkpoint inhibitor therapy is warranted, Daniel P. Petrylak, MD, professor of medicine and urology and chief of genitourinary oncology at Yale